Core Viewpoint - The use of capital reserve to cover losses by listed companies is being implemented, but it is essential to balance the interests of all parties involved, particularly the protection of creditors' rights [1][2][3] Group 1: Regulatory Framework - The new Company Law stipulates that companies must first use discretionary and statutory reserves before utilizing capital reserves to cover losses [1] - The Ministry of Finance issued a notification that outlines the financial regulations regarding the use of capital reserves, including the requirement for board resolutions to be submitted for shareholder approval [1] - The notification emphasizes the need to protect creditor interests, mandating companies to notify creditors within thirty days of the shareholder resolution [1][2] Group 2: Creditor Protection - Companies must provide reasonable assessments of their debt repayment capabilities to creditors to mitigate misunderstandings [2] - The "unsettled defense right" under the Civil Code allows creditors to suspend contract obligations if they have evidence of the debtor's deteriorating financial condition [2] - If the use of capital reserves leads to a decline in the core capital adequacy ratio by more than 30%, creditors may have the right to demand collateral or accelerate debt repayment [2] Group 3: Impact on Financial Health - Utilizing capital reserves does not genuinely affect a company's actual profitability, and stricter regulations may be necessary to manage the interests of various stakeholders [3] - Companies with significant losses or those classified as ST (Special Treatment) should be prohibited from using capital reserves to cover losses, while strategic emerging industries with high R&D intensity may have relaxed rules [3] - Companies are restricted from share buybacks or large cash dividends within 12 months after using capital reserves to cover losses [3] Group 4: Recommendations for Improvement - Regulatory bodies should enhance guidance and monitoring of companies using capital reserves to ensure stable profitability [3] - Companies should develop actionable plans for turning losses into profits and be transparent in their operations to regain market trust [3] - The use of capital reserves should not serve as a tool for concealing financial issues but should aim to facilitate recovery and compliance within a secure framework [3]

Group 1 - The high-pressure oxygen chamber concept increased by 1.55%, ranking second among concept sectors, with three stocks rising, including a 20% limit up for Tiebian Heavy Industry [1] - The leading gainers in the high-pressure oxygen chamber sector were International Medicine and Yinkang Life, which rose by 0.93% and 0.20% respectively [1] - The sector saw a net inflow of 0.50 billion yuan from main funds, with Tiebian Heavy Industry receiving the highest net inflow of 1.03 billion yuan [2][3] Group 2 - The main fund inflow ratios for Tiebian Heavy Industry, International Medicine, and Jinling Pharmaceutical were 29.36%, 10.10%, and 5.54% respectively [3] - The trading performance of stocks in the high-pressure oxygen chamber sector showed varied results, with Tiebian Heavy Industry leading in both price increase and fund inflow [3][4] - Stocks such as Weiao and Innovation Medical experienced significant declines, with net outflows of -3214.35 million yuan and -4427.60 million yuan respectively [4]

Group 1 - The high-pressure oxygen chamber concept increased by 2.63%, ranking 10th among concept sectors, with five stocks rising, including a 20% limit-up for Tiedao Heavy Industry [1] - Notable gainers in the high-pressure oxygen chamber sector include Innovation Medical and Samsung Medical, which rose by 3.29% and 0.96% respectively [1] - The sector experienced a net inflow of 170 million yuan from main funds, with Tiedao Heavy Industry receiving the highest net inflow of 120 million yuan [2] Group 2 - The top stocks by net inflow ratio in the high-pressure oxygen chamber sector are Tiedao Heavy Industry at 39.19%, International Medical at 4.88%, and Samsung Medical at 4.16% [3] - The trading volume and turnover rates for key stocks in the sector indicate significant investor interest, with Tiedao Heavy Industry showing a turnover rate of 0.97% [3] - Decliners in the sector included Dahu Co., which fell by 0.55%, and Aoyang Health, which decreased by 0.50% [4]

证券代码：300143 证券简称：盈康生命 公告编号：2025-035 沈旭东先生符合《公司法》《公司章程》规定的有关职工代表董事任职资格和 条件。沈旭东先生当选公司职工代表董事后，公司第六届董事会中兼任公司高级管 理人员以及由职工代表担任的董事人数未超过公司董事总数的二分之一，符合相关 法律法规的要求。 盈康生命科技股份有限公司 关于董事辞任暨选举职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、关于非独立董事辞任的情况 盈康生命科技股份有限公司（以下简称"公司"）董事会收到公司非独立董事 沈旭东先生的书面辞任报告。因公司内部工作调整，沈旭东先生申请辞去公司第六 届董事会非独立董事职务，原定任期到2026年9月27日，辞任后仍担任公司相关职 务。沈旭东先生的辞任不会导致公司董事会人数低于法定最低人数，其辞任报告自 送达公司董事会之日起生效。 截至本公告披露日，沈旭东先生持有公司股份41,497股，占公司总股本的 0.0055%。沈旭东先生此次职位变动后，将继续严格遵守《公司法》《上市公司董 事和高级管理人员所持本公司股份及其变动管理规则 ...

Group 1 - The high-pressure oxygen chamber concept increased by 3.78%, ranking 8th among concept sectors, with 8 stocks rising, including a 20% limit up for Tiebian Heavy Industry [1] - The leading stocks in the high-pressure oxygen chamber sector included Weiao Co., International Medicine, and Dahu Co., which rose by 3.80%, 3.24%, and 2.44% respectively [1] - The high-pressure oxygen chamber sector saw a net inflow of 152 million yuan from main funds, with 6 stocks receiving net inflows, and 5 stocks exceeding 10 million yuan in net inflow [2] Group 2 - The top net inflow stock was Tiebian Heavy Industry, with a net inflow of 60.89 million yuan, followed by International Medicine, Samsung Medical, and Aoyang Health with net inflows of 57.53 million yuan, 42.20 million yuan, and 22.89 million yuan respectively [2] - In terms of net inflow ratios, Aoyang Health, Tiebian Heavy Industry, and International Medicine had the highest ratios at 15.77%, 14.47%, and 11.68% respectively [3] - The trading performance of stocks in the high-pressure oxygen chamber sector showed significant activity, with Tiebian Heavy Industry achieving a daily increase of 19.90% and a turnover rate of 1.60% [3]

Group 1 - The company plans to use a total of 1.458 billion yuan from its surplus and capital reserves to cover accumulated losses, primarily due to asset impairment from acquisitions made before Haier's takeover [1] - The losses are attributed to prior years' asset impairment losses and investment losses from the transfer of subsidiary equity, mainly related to assets acquired before Haier's involvement [1] - This financial restructuring is a common practice for listed companies to optimize their financial structure and is in line with the new Company Law and relevant guidelines from the Ministry of Finance [1] Group 2 - The financial adjustment is not a reactive measure due to operational pressure; the company has achieved steady profitability, with a net profit of 100 million yuan in 2023, a year-on-year increase of 116.9% [2] - Projected net profit for 2024 is 115 million yuan, reflecting a growth of 14.92%, and the company started 2025 with a strong first quarter net profit of 29.99 million yuan [2] - The company is entering a new development phase, driven by the dual engines of medical services and high-end medical devices, enhanced by "medical + AI" technology [2]

Core Viewpoint - Yingkang Life plans to use 1.458 billion yuan from its capital reserve to offset accumulated losses, aiming to clear its balance sheet losses and reset its undistributed profits to zero, which reflects a strategic financial maneuver rather than a fundamental operational recovery [2][3] Financial Strategy - The company reported a net profit of 29.99 million yuan and revenue of 409 million yuan in Q1 2025, indicating initial success in its restructuring efforts, but this profit is insufficient to cover previous substantial losses [3] - The use of capital reserves to offset losses is a compliant financial arrangement that may restore the company's refinancing capabilities and future profit distribution potential [2] Operational Concerns - Despite the accounting maneuver, the actual operational performance remains critical; the company must demonstrate sustainable profitability rather than relying on one-time financial improvements [3] - The significant losses in recent years stem from asset impairments and investment losses related to subsidiary equity disposals, highlighting weaknesses in investment management and business strategy [2] Market Sentiment - The market reaction to loss offsetting strategies is mixed; while it may enhance the potential for future dividends and provide some stock price support, investors remain focused on the company's fundamental business model and risk management capabilities [3] - The case of Yingkang Life serves as a cautionary tale for other listed companies regarding the risks of aggressive expansion and diversification without sound management practices [3] Future Outlook - The ability of Yingkang Life to truly pivot and establish a growth trajectory will be a key focus for market observers, as financial adjustments alone cannot ensure long-term value [3]

Group 1 - The company held its 19th (temporary) meeting of the sixth board of directors on July 16, 2025, with all 9 directors present, either in person or via communication methods [1][2] - The board approved the proposal to use surplus reserves to cover losses, utilizing a total of 1,457,808,920.00 yuan from surplus reserves and capital reserves [1][2] - The proposal received unanimous support with 9 votes in favor and will be submitted to the shareholders' meeting for further approval [2] Group 2 - The company has scheduled its second temporary shareholders' meeting for 2025 on August 1, 2025, to be held in Qingdao, combining in-person attendance with online voting [2] - The proposal for the shareholders' meeting was also unanimously approved with 9 votes in favor [2]

证券代码：300143 证券简称：盈康生命 公告编号：2025-034 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》《公司章程》的有关规定，经盈康生命科技股 份有限公司（以下简称"公司"）第六届董事会第十九次（临时）会议审议通过， 决定于2025年8月1日14:30召开公司2025年第二次临时股东会，现将有关事项通知 如下： 一、召开会议的基本情况 行政法规、部门规章、规范性文件、深圳证券交易所业务规则和《公司章程》的 规定。 （1）现场会议时间：2025年8月1日（星期五）14:30 开，公司股东应选择现场投票、网络投票中的一种方式，如果同一表决权出现重 复投票表决的，以第一次投票表决结果为准。公司将通过深圳证券交易所交易系 统和互联网投票系统（http://wltp.cninfo.com.cn）向全体股东提供网络形式的投票 平台，公司股东可在网络投票时间内通过上述系统行使表决权。 （1）于 2025 年 7 月 25 日下午收市时在中国证券登记结算有限责任公司深 圳分公司登记在册的公司全体股东。上述股东均有权出席股东会并行使 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 盈康生命科技股份有限公司（以下简称"公司"）于2025年7月16日召开了第 六届董事会第十九次（临时）会议审议通过了《关于公司使用公积金弥补亏损的议 案》，为积极推动公司高质量发展，提升投资者回报能力和水平，保护投资者特别 是中小投资者的合法权益，公司拟按照相关规定使用公积金弥补亏损。此举将有效 改善公司财务状况，使公司符合法律法规和《公司章程》规定的利润分配条件，为 公司后续健康发展奠定基础。该议案尚需公司股东会审议。现将具体情况公告如下： 一、本次使用公积金弥补亏损的基本情况 根据和信会计师事务所（特殊普通合伙）出具的和信审字（2025）第000336号 标准无保留意见的《审计报告》，截至2024年12月31日，公司母公司报表的未分配 利润为-1,457,808,920.00元，盈余公积9,726,169.55元，资本公积为3,462,652,293.44 元。 根据《中华人民共和国公司法》、财政部《关于公司法、外商投资法施行后有 关财务处理问题的通知》（财资〔2025〕101号）等法律、法规及规范性文件，以 ...